Hatch-Waxman Improvement Act of 2022

12/29/2022, 5:33 PM

Hatch-Waxman Improvement Act of 2022

This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).

Congress
117
Number
S - 4378
Introduced on
2022-06-13
# Amendments
0
Sponsors
+5

Variations and Revisions

6/13/2022
Text
PDF
XML

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Hatch-Waxman Improvement Act of 2022

This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).

Alternative Names
Official Title as IntroducedA bill to reauthorize a provision of the Federal Food, Drug, and Cosmetic Act pertaining to drugs containing single enantiomers.
Policy Areas
Health

Comments

Recent Activity

Latest Summary10/18/2022

Hatch-Waxman Improvement Act of 2022

This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of...

Latest Action6/13/2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.